



THE MEDICAL FOUNDATION

Your Laboratory Experts

Our Pain Management Program

Clinical Significance of Pain Management Testing

Pain is not easily defined given the variability in perception that exists from person to person but may be generally categorized as an unpleasant sensory experience associated with emotional stress and/or bodily disorders.

Pain may be of short duration (acute), usually the result of injury, illness, or surgery; or ongoing and recurring (chronic) caused by conditions such as nerve damage, musculoskeletal disorders, and disease processes such as cancer.

It is estimated that 86 million American adults are affected by chronic pain to some degree. Utilization of pain management treatment plans for acute and chronic pain suffering populations may reduce the severity of pain, minimize further health problems and enhance quality of life.

Effective pain management treatment plans often require a pharmacological intervention (i.e., use of prescription pain medications). To ensure the safety and effectiveness of such treatment plans, routine urine drug screen testing is essential.



In 1975, South Bend Medical Foundation designated Toxicology as a specialized department. New test methodologies were researched to meet the growing needs of the medical community for therapeutic drug monitoring and drug abuse testing.

The advent of chemical dependency centers escalated the need for a sophisticated toxicology laboratory, which the Medical Foundation was prepared to meet. In mid-1980, the Toxicology Department evolved into a testing site, evaluating procedures and quality assurance controls for companies producing clinical laboratory testing products.

An important aspect of an effective pain management program is the selection of a laboratory to perform the testing. The Medical Foundation has not only developed drug-screening programs that meet the high quality testing standards demanded by the sensitivity of such a program, but also maintains the latest technology, staying on the forefront of pain management testing.

How are results of Pain Management tests used?

Use of a pain management panel for routine drug testing assists in identifying: patient compliance with prescribed drug regimen, illicit drug abuse, and drug diversion (distribution, exchange or sale of prescribed medication).

Panels A & B without Reflex

Pain Management Panel A (14 Drugs), Urine

Order: PMPA Test # 31472
 CPT Code 80301; 80302x3 (Medicare: G0434)
 Testing dates: Monday - Friday
 Specimen: 20mL Urine, Minimum 10mL
 Type of Container: Sterile urine container
 Storage/ Transport: Refrigerated
 Cause for rejection: Sample other than urine
 Stability: 1 week refrigerated, 1 month frozen

<u>DRUGS/DRUG CLASSES</u>	<u>EIA CUTOFF</u>
Buprenorphine	10 ng/mL
Fentanyl	2.0 ng/mL
Meperidine	100 ng/mL
Methadone	300 ng/mL
Oxycodone	100 ng/mL
Propoxyphene	300 ng/mL
Tramadol	100 ng/mL
Barbiturates	200 ng/mL
Amphetamines	500 ng/mL
Cocaine Metabolite	150 ng/mL
Marijuana Metabolite	50 ng/mL
Phencyclidine	25 ng/mL
Benzodiazepines	100 ng/mL
Opiates	300 ng/mL
<u>SPECIMEN VALIDITY</u>	<u>EXPECTED</u>
Oxidant Screen	[≤ 199]
Creatinine	[> 20 mg/dL]
pH Screen	[4.5 - 8.9]

Pain Management Panel B (10 Drugs), Urine

Order: PMPB Test # 31474
 CPT Code 80301; 80302x3 (Medicare: G0434)
 Testing dates: Monday - Friday
 Specimen: 20mL Urine, Minimum 10mL
 Type of Container: Sterile urine container
 Storage/ Transport: Refrigerated
 Cause for rejection: Sample other than urine
 Stability: 1 week refrigerated, 1 month frozen

<u>DRUGS/DRUG CLASSES</u>	<u>EIA CUTOFF</u>
Buprenorphine	10 ng/mL
Fentanyl	2.0 ng/mL
Meperidine	100 ng/mL
Methadone	300 ng/mL
Oxycodone	100 ng/mL
Propoxyphene	300 ng/mL
Tramadol	100 ng/mL
Barbiturates	200 ng/mL
Benzodiazepines	100 ng/mL
Opiates	300 ng/mL
<u>SPECIMEN VALIDITY</u>	<u>EXPECTED</u>
Oxidant Screen	[≤ 199]
Creatinine	[> 20 mg/dL]
pH Screen	[4.5 - 8.9]

Panel A with Reflex

Pain Management Panel A (14 Drugs) with Reflex to Confirmation/ Quantitation, Urine

Order: PMPA/C Test # 31473
 CPT Code 80301; 80302x3 (Medicare: G0434)
 Testing dates: Monday - Friday
 Specimen: 20mL Urine, Minimum 10mL

Type of Container: Sterile urine container
 Storage/ Transport: Refrigerated
 Cause for rejection: Sample other than urine
 Stability: 1 week refrigerated, 1 month frozen

<u>DRUGS/DRUG CLASSES</u>	<u>EIA CUTOFF</u>	<u>GC/MS CUTOFF</u>
Buprenorphine	10 ng/mL	Confirms: Buprenorphine (2.0 ng/mL) Buprenorphine metabolites (2.0 -5.0 ng/mL)
Fentanyl	2.0 ng/mL	Confirms: Fentanyl (1.0 ng/mL) Norfentanyl (1.0 ng/mL)
Meperidine	100 ng/mL	Confirms: Meperidine (2.0 ng/mL) Normeperidine (5.0 ng/mL)
Methadone	300 ng/mL	Confirms: Methadone (10 ng/mL) EDDP (10 ng/mL)
Oxycodone	100 ng/mL	Confirms: Oxycodone (20 ng/mL) Confirms: Oxymorphone (20 ng/mL)
Propoxyphene	300 ng/mL	Confirms: Propoxyphene (10 ng/mL) Propoxyphene metabolite (Qualitative)
Tramadol	100 ng/mL	Confirms: Tramadol (50 ng/mL) n-desmethyltramadol (100 ng/mL) o-desmethyltramadol (100 ng/mL)
Barbiturates	200 ng/mL	Confirms: Butalbital (50 ng/mL) Amobarbital (50 ng/mL) Pentobarbital (50 ng/mL) Secobarbital (50 ng/mL) Phenobarbital (50 ng/mL)
Amphetamines	500 ng/mL	Confirms: Amphetamine (200 ng/mL) Methamphetamine (200 ng/mL) Methylenedioxyamphetamine (MDA) (200 ng/mL) Methylenedioxyamphetamine (Ecstasy, MDMA)(200 ng/mL) Methylenedioxyethylamphetamine (Eve, MDEA) (200 ng/mL)
Cocaine Metabolite	150 ng/mL	Confirms: Benzoylcegonine (50 ng/mL)
Marijuana Metabolite	50 ng/mL	Confirms: 9-Carboxy-THC (5 ng/mL)
Phencyclidine	25 ng/mL	Confirms: Phencyclidine (PCP) (25 ng/mL)
Benzodiazepines	100 ng/mL	Confirms: Nordiazepam (20 ng/mL) Oxazepam (20 ng/mL) Lorazepam (20 ng/mL) Temazepam (20 ng/mL) 7-Amino-Clonazepam (20 ng/mL) Alpha-Hydroxy-Midazolam (20 ng/mL) Alpha-Hydroxy-Alprazolam (20 ng/mL)
Opiates	300 ng/mL	Confirms: Codeine (20 ng/mL) Hydrocodone (20 ng/mL) Hydromorphone (20 ng/mL) 6-Acetylmorphine (20 ng/mL) Morphine (20 ng/mL) Oxycodone (20 ng/mL) Oxymorphone (20 ng/mL) Dihydrocodeine (20 ng/mL)
<u>SPECIMEN VALIDITY</u>	<u>EXPECTED</u>	
Oxidant Screen	[≤ 199]	
Creatinine	[> 20 mg/dL]	
pH Screen	[4.5 - 8.9]	

Panel B with Reflex

Pain Management Panel B (10 Drugs) with Reflex to Confirmation/ Quantitation, Urine

Order: PMPB/C Test # 31475
CPT Code 80301; 80302x3 (Medicare: G0434)
Testing dates: Monday - Friday
Specimen: 20mL Urine, Minimum 10mL

Type of Container: Sterile urine container
Storage/ Transport: Refrigerated
Cause for rejection: Sample other than urine
Stability: 1 week refrigerated, 1 month frozen

<u>DRUGS/DRUG CLASSES</u>	<u>EIA CUTOFF</u>	<u>GC/MS CUTOFF</u>
Buprenorphine	10 ng/mL	Confirms: Buprenorphine (2.0 ng/mL) Buprenorphine metabolites (2.0 -5.0 ng/mL)
Fentanyl	2.0 ng/mL	Confirms: Fentanyl (1.0 ng/mL) Norfentanyl (1.0 ng/mL)
Meperidine Normeperidine (5.0 ng/mL)	100 ng/mL	Confirms: Meperidine (2.0 ng/mL)
Methadone EDDP (10 ng/mL)	300 ng/mL	Confirms: Methadone (10 ng/mL)
Oxycodone Confirms: Oxymorphone (20 ng/mL)	100 ng/mL	Confirms: Oxycodone (20 ng/mL)
Propoxyphene Propoxyphene metabolite (Qualitative)	300 ng/mL	Confirms: Propoxyphene (10 ng/mL)
Tramadol	100 ng/mL	Confirms: Tramadol (50 ng/mL) n-desmethyltramadol (100 ng/mL) o-desmethyltramadol (100 ng/mL)
Barbiturates	200 ng/mL	Confirms: Butalbital (50 ng/mL) Amobarbital (50 ng/mL) Pentobarbital (50 ng/mL) Secobarbital (50 ng/mL) Phenobarbital (50 ng/mL)
Benzodiazepines	100 ng/mL	Confirms: Nordiazepam (20 ng/mL) Oxazepam (20 ng/mL) Lorazepam (20 ng/mL) Temazepam (20 ng/mL) 7-Amino-Clonazepam (20 ng/mL) Alpha-Hydroxy-Midazolam (20 ng/mL) Alpha-Hydroxy-Alprazolam (20 ng/mL)
Opiates	300 ng/mL	Confirms: Codeine (20 ng/mL) Hydrocodone (20 ng/mL) Hydromorphone (20 ng/mL) 6-Acetylmorphine (20 ng/mL) Morphine (20 ng/mL) Oxycodone (20 ng/mL) Oxymorphone (20 ng/mL) Dihydrocodeine (20 ng/mL)

<u>SPECIMEN VALIDITY</u>	<u>EXPECTED</u>
Oxidant Screen	[≤ 199]
Creatinine	[> 20 mg/dL]
pH Screen	[4.5 – 8.9]

Panel C with Reflex

Pain Management Panel C (15 Drugs) with Reflex to Confirmation/ Quantitation, Urine

Order: PMPC/C Test # 35495
CPT Code 80301; 80302x4 (Medicare: G0434)
Testing dates: Monday - Friday
Specimen: 20mL Urine, Minimum 10mL

Type of Container: Sterile urine container
Storage/ Transport: Refrigerated
Cause for rejection: Sample other than urine
Stability: 1 week refrigerated, 1 month frozen

<u>DRUGS/DRUG CLASSES</u>	<u>EIA CUTOFF</u>	<u>GC/MS CUTOFF</u>
Buprenorphine	10 ng/mL	Confirms: Buprenorphine (2.0 ng/mL) Buprenorphine metabolites (2.0 -5.0 ng/mL)
Fentanyl	2.0 ng/mL	Confirms: Fentanyl (1.0 ng/mL) Norfentanyl (1.0 ng/mL)
Meperidine	100 ng/mL	Confirms: Meperidine (2.0 ng/mL) Normeperidine (5.0 ng/mL)
Methadone	300 ng/mL	Confirms: Methadone (10 ng/mL) EDDP (10 ng/mL)
Oxycodone	100 ng/mL	Confirms: Oxycodone (20 ng/mL) Confirms: Oxymorphone (20 ng/mL)
Propoxyphene	300 ng/mL	Confirms: Propoxyphene (10 ng/mL) Propoxyphene metabolite (Qualitative)
Tramadol	100 ng/mL	Confirms: Tramadol (50 ng/mL) n-desmethyltramadol (100 ng/mL) o-desmethyltramadol (100 ng/mL)
Barbiturates	200 ng/mL	Confirms: Butalbital (50 ng/mL) Amobarbital (50 ng/mL) Pentobarbital (50 ng/mL) Secobarbital (50 ng/mL) Phenobarbital (50 ng/mL)
Amphetamines	500 ng/mL	Confirms: Amphetamine (200 ng/mL) Methamphetamine (200 ng/mL) Methylenedioxyamphetamine (MDA) (200 ng/mL) Methylenedioxymethamphetamine (Ecstasy, MDMA)(200 ng/mL) Methylenedioxyethylamphetamine (Eve, MDEA) (200 ng/mL)
Cocaine Metabolite	150 ng/mL	Confirms: Benzoylecgonine (50 ng/mL)
Marijuana Metabolite	50 ng/mL	Confirms: 9-Carboxy-THC (5 ng/mL)
Phencyclidine	25 ng/mL	Confirms: Phencyclidine (PCP) (25 ng/mL)
Benzodiazepines	100 ng/mL	Confirms: Nordiazepam (20 ng/mL) Oxazepam (20 ng/mL) Lorazepam (20 ng/mL) Temazepam (20 ng/mL) 7-Amino-Clonazepam (20 ng/mL) Alpha-Hydroxy-Midazolam (20 ng/mL) Alpha-Hydroxy-Alprazolam (20 ng/mL)
Opiates	300 ng/mL	Confirms: Codeine (20 ng/mL) Hydrocodone (20 ng/mL) Hydromorphone (20 ng/mL) 6-Acetylmorphine (20 ng/mL) Morphine (20 ng/mL) Oxycodone (20 ng/mL) Oxymorphone (20 ng/mL) Dihydrocodeine (20 ng/mL)
Carisoprodol	100 ng/mL	Confirms: Carisoprodol (100 ng/mL) Meprobamate (100 ng/mL)

<u>SPECIMEN VALIDITY</u>	<u>EXPECTED</u>
Oxidant Screen	[≤ 199]
Creatinine	[> 20 mg/dL]
pH Screen	[4.5 – 8.9]

Panel D with Reflex

Pain Management Panel D (8 Drugs) with Reflex to Confirmation/ Quantitation, Urine

Order: PMPD/C Test # 31479
CPT Code 80301; 80302x2 (Medicare: G0434)
Testing dates: Monday - Friday
Specimen: 20mL Urine, Minimum 10mL

Type of Container: Sterile urine container
Storage/ Transport: Refrigerated
Cause for rejection: Sample other than urine
Stability: 1 week refrigerated, 1 month frozen

<u>DRUGS/DRUG CLASSES</u>	<u>EIA CUTOFF</u>	<u>GC/MS CUTOFF</u>
Meperidine	100 ng/mL	Confirms: Meperidine (2.0 ng/mL) Normeperidine (5.0 ng/mL)
Methadone	300 ng/mL	Confirms: Methadone (10 ng/mL) EDDP (10 ng/mL)
Oxycodone	100 ng/mL	Confirms: Oxycodone (20 ng/mL) Confirms: Oxymorphone (20 ng/mL)
Tramadol	100 ng/mL	Confirms: Tramadol (50 ng/mL) n-desmethyltramadol (100 ng/mL) o-desmethyltramadol (100 ng/mL)
Amphetamines	500 ng/mL	Confirms: Amphetamine (200 ng/mL) Methamphetamine (200 ng/mL) Methylenedioxyamphetamine (MDA) (200 ng/mL) Methylenedioxymethamphetamine (Ecstasy, MDMA)(200 ng/mL) Methylenedioxyethylamphetamine (Eve, MDEA) (200 ng/mL)
Cocaine Metabolite	150 ng/mL	Confirms: Benzoylcegonine (50 ng/mL)
Benzodiazepines	100 ng/mL	Confirms: Nordiazepam (20 ng/mL) Oxazepam (20 ng/mL) Lorazepam (20 ng/mL) Temazepam (20 ng/mL) 7-Amino-Clonazepam (20 ng/mL) Alpha-Hydroxy-Midazolam (20 ng/mL) Alpha-Hydroxy-Alprazolam (20 ng/mL)
Opiates	300 ng/mL	Confirms: Codeine (20 ng/mL) Hydrocodone (20 ng/mL) Hydromorphone (20 ng/mL) 6-Acetylmorphine (20 ng/mL) Morphine (20 ng/mL) Oxycodone (20 ng/mL) Oxymorphone (20 ng/mL) Dihydrocodeine (20 ng/mL)

SPECIMEN VALIDITY

Oxidant Screen
Creatinine
pH Screen

EXPECTED

[\leq 199]
[> 20 mg/dL]
[4.5 – 8.9]